{"groups":[{"description":"The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.\n\n* Ibrutinib will be administered at a predetermined dose, once daily for 28 days\n* TLS Prophylaxis (Treatment to reduce risk of tumor lysis syndrome) prior to first dose of venetoclax (and for at least the first 2 weeks of treatment)\n* Venetoclax Cycle 2-24. PO daily, predetermined dosage ramp up during cycle 2.\n\nIBRUTINIB: Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days\n\nVenetoclax: Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.","id":"FG000","title":"Ibrutinib and Venetoclax"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"45"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"45"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}